Acute Myeloid Leukemia Clinical Trial
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Summary
This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.
Eligibility Criteria
Inclusion Criteria:
Patients must have a Karnofsky (adult) Performance Status of at least 70%.
Patients must have adequate organ function
Exclusion Criteria:
Female patients who are pregnant or breast-feeding
Active viral, bacterial or fungal infection
Patient seropositive for Human Immunodeficiency Virus (HIV-I /II); Human T-Cell Lymphotrophic Virus (HTLV -I /II)
Presence of leukemia in the Central Nervous System (CNS).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Miami Florida, 33176, United States More Info
Principal Investigator
How clear is this clinincal trial information?